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Sir, Dr Greenberg misinterprets several important aspects of our
study, including the scope and applied methodology. Below we
have addressed the points raised in his correspondence.
This was a proof-of principle molecular clinicopathological study
designed to investigate the effect of alemtuzumab on endomysial
T cells and disease progression; it was not primarily a trial of
clinical efﬁcacy. As stated, alemtuzumab did not signiﬁcantly
improve patients’ strength and function but only induced short-
term stability based on the difference between two time periods.
Contrary to Dr Greenberg’s comments, outcome was not based on
any predetermined percentages that were subsequently amended.
The percentages mentioned by Dr Greenberg were used only to
power the sample size. As our results show, these percentages do
not relate to the outcome or conclusions of the study because,
regardless of whether a 10%, 13% or 15% difference is used, there
isnosigniﬁcantimprovementinthepatients’strength(ashecorrectly
points out, only 4 of 13 patients improved, by only 4%–19%,
while the mean strength for all patients declined by 1.9%).
Our data and the interpretation of results have now been
ratiﬁed in an independent review by the National Institutes of
Health. The main ﬁnding was a signiﬁcant reduction of relevant
molecules seen in repeated muscle biopsies, combined with short-
term clinical stability; this is encouraging and, as we stressed,
warrants a controlled study. One should not read more than
that from these results. The study was arguably small and
uncontrolled but taught us a lot about the pathogenesis of
inclusion body myositis; it was not designed to demonstrate
clinical efﬁcacy and we do not recommend alemtuzumab as a
treatment for inclusion body myositis.
Regarding Dr Greenberg’s speciﬁc points (and necessarily
restating some of our general responses already outlined), our
comments are as follows:
(i) Introduction to his letter and points (i) and (vii): we
had indeed reported, at two scientiﬁc meetings 2 years
ago, preliminary data showing that 6 of 13 patients
improved by 4%–35%. In the Brain paper, we reported
that only 4 of 13 patients improved, by only 4%–19%.
This indicates: (a) care in the ﬁnal analysis which was
repeated several times to ensure accuracy; and (b) publica-
tion of unbiased data, describing a lower number of patients
that gained strength, rather than overinﬂating the results.
There was no statistical improvement in the patients’
strength, regardless of whether a 10%, 13% or 15%
predetermined change was used during analysis. We did
not suggest that such a minor change was signiﬁcant.
The clinical end-point was the induction of 6 months stabil-
ity, based on the difference between the two time periods,
not a predetermined percentage change. The percentages of
15% and 10% that Dr Greenberg mentions were only used
to calculate the sample size. As stated in our manuscript,
when referring to the number of patients needed, ‘power
analysis was not performed for detecting changes in disease
progression as the percentage of strength decline was not
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change was mentioned in the original protocol to calculate a
conservative sample size. Because stability, not improve-
ment, was the primary target of the study, we
estimated—based on the early quantitative muscle strength
testing observations which showed55% variability from test
to test—that a 10% change was sufﬁcient to capture stabil-
ity and complete the study with a smaller number of
patients. Terminating the study with a lesser number of
patients was communicated to the Institutional Review
Board. The web site at clinicaltrials.gov, quoted by
Dr Greenberg, lists only the original abstract of the study.
This web site is renewed automatically only to bring
the registration up to date by the National Institutes of
Health Clinical Centre, without further input from the
investigator.
(ii) Points (ii) and (iii): we did compare the decline of 12 months
to that of a change observed after 6 months of treatment.
We feel that these comparative periods are the most
appropriate to capture meaningful changes because previous
studies have not shown much decline over a 6-month
natural history period (Rose et al., 2001). Therefore, we
do not feel that comparing the changes to those of
6 months would have been more meaningful clinically.
(iii) Point (iv): one episode of lymphapheresis, prior to the study,
will not affect the efﬁcacy of alemtuzumab 6 months later
because: (a) as shown in a previous controlled study,
lymphapheresis has no beneﬁcial effect in inﬂammatory
myopathies, even if given as several courses (Miller et al.,
1992); and (b) there was no resultant signiﬁcant reduction
of lymphocytes causing a long-lasting effect, which
might have contributed to the effects of alemtuzumab.
(iv) Point (v): the suggestion that the prophylactic administration
of valgancyclovir may have confounded the results is
unlikely to be correct. Although we have theorized that
inclusion body myositis may be triggered by a virus, neither
we, nor others, have identiﬁed DNA viruses in muscle
biopsies from patients with inclusion body myositis.
(v) Point (vi): the noted peripheral blood lymphocyte reduction
initially starts as a depletion. We chose the 6 month period
because previous studies have shown consistent reductions
up to that point. Since this was a clinicopathological study,
we also chose the 6 month period as the best time to assess
any reduction of endomysial lymphocytes in the repeated
biopsies and any changes in clinical measurements.
(vi) Point (viii): we brieﬂy addressed the difference between
quantitative muscle strength testing and Medical Research
Council measurements in the paper. It is well known
that all methods of muscle strength assessment, from
computer-assisted to manual techniques, have inherent lim-
itations. Given the differences in positioning, precision,
scoring criteria and scale of measurement, it is not surprising
that the quantitative muscle strength and Medical Research
Council scoring do not reﬂect equivalent changes in strength
(Tiffreau, 2007). One of several things we learned from this
study is the importance of having a performance-based
functional assessment. Future studies will favour
performance-based functional measures in addition to
impairment-based outcomes, to assess clinical changes.
Such scales have been used both in amyotrophic lateral
sclerosis trials and in multiple sclerosis trials for a long
time. There is already a good effort to create such scales
in inclusion body myositis (Jackson et al., 2008).
(vii) Points (ix) and (x): we agree that assessment bias and
placebo effect are important factors but both are unavoid-
able in uncontrolled studies. This is the reason we stated in
the paper that a ‘placebo effect could not be excluded’
and recommended a controlled study.
We are enthusiastic about exploring further the use of
alemtuzumab based on the signiﬁcant short-term stability that
we describe. Since publication, the National Institute of
Neurological Disorders and Stroke requested an independent
review of our paper and we are happy to conﬁrm that the results
have been independently veriﬁed; and our main message, that
‘the rate of strength decline 6 months after alemtuzumab was
signiﬁcantly reduced compared with the 12 month natural history
period’ was ratiﬁed.
The signiﬁcant modulation of relevant molecules in the repeated
muscle biopsies, along with the noted strength gains in some
patients, has been informative with respect to the pathogenesis
of inclusion body myositis. We are pleased to have completed
a difﬁcult clinicopathological study, one of the few of its kind,
and grateful to all our patients for contributing to the study.
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